Assessment of Ospemifene or Lubricants on Clinical Signs of VVA

Ospemifene substantially improved clinical signs of VVA. Within the placebo group, there was no difference in physiologic effects in lubricant users vs. nonusers. Based on gynecologic evaluation of the vagina, benefits were apparent at 12 weeks and sustained for 52 weeks in the ospemifene‐treated subjects with significant improvement over placebo. In these three clinical trials, in contrast to ospemifene‐treated women, placebo subjects who utilized lubricants had no improvement in their underlying vaginal physiology. Constantine G, Graham S, Koltun WD, and Kingsberg SA. Assessment of ospemifene or lubricants on clinical signs of VVA. J Sex Med 2014;11:1033-1041.